CHA₂DS₂ VA Score Calculator for Atrial Fibrillation

Clinical calculation support · Verify results before clinical use

Thromboembolic Risk Assessment

Enter the patient's age and select each applicable clinical risk factor. The score is calculated when you submit the form.

—Score / 8

Patient age

Age 65–74 years contributes 1 point; age 75 years or older contributes 2 points. Age points are mutually exclusive.

Clinical risk factors

About the CHA2DS2-VA score

The CHA2DS2-VA score supports thromboembolic risk assessment and oral anticoagulation decisions in patients with atrial fibrillation. The 2024 European Society of Cardiology (ESC) guideline uses the score without a sex-category component.

ComponentDefinitionPoints
CChronic heart failure1
HHypertension1
A₂Age ≥75 years2
DDiabetes mellitus1
S₂Previous stroke, TIA, or arterial thromboembolism2
VVascular disease1
AAge 65–74 years1

Interpretation thresholds in the 2024 ESC guideline

  • Score 0: oral anticoagulation is generally not indicated based on this score alone; consider other risk modifiers.
  • Score 1: oral anticoagulation should be considered through individualized, shared decision-making.
  • Score ≥2: oral anticoagulation is recommended for eligible patients with clinical AF, unless contraindicated.

Clinical considerations

Risk is dynamic. Reassess thromboembolic risk periodically and when clinical characteristics change, including age, hypertension, diabetes, heart failure, or vascular disease.

Additional risk modifiers may affect decisions and should be considered in context. The score is not a substitute for clinical assessment or shared decision-making.

Bleeding risk assessment should help identify modifiable risks and guide follow-up. A bleeding score should not, by itself, determine whether anticoagulation is initiated or withdrawn.

Important exceptions

The 2024 ESC guideline recommends oral anticoagulation in patients with atrial fibrillation and hypertrophic cardiomyopathy or cardiac amyloidosis regardless of CHA2DS2-VA score. Confirm individual indications, contraindications, and anticoagulant choice against current guidance.

References

Van Gelder IC, Rienstra M, Bunting KV, et al. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS).European Heart Journal. 2024;45(36):3314–3414. doi:10.1093/eurheartj/ehae176. PMID: 39210723. DOI / official journal article · PubMed
European Society of Cardiology. 2024 Guidelines for the management of atrial fibrillation.Official guideline overview and supporting materials. ESC guideline page